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Low affinity receptors for the Fc portion of IgG (FcγRs) represent a critical link between
innate and adaptive immunity. Immune complexes (ICs) are the natural ligands for low
affinity FcγRs, and high levels of ICs are usually detected in both, chronic viral infections
and autoimmune diseases. The expression and function of FcγRs in myeloid cells, NK
cells and B cells have been well characterized. By contrast, there are controversial reports
about the expression and function of FcγRs in T cells. Here, we demonstrated that ∼2%
of resting CD4+ T cells express cell surface FcγRII (CD32). Analysis of CD32 expression
in permeabilized cells revealed an increased proportion of CD4+CD32+ T cells (∼9%),
indicating that CD4+ T cells store a CD32 cytoplasmic pool. Activation of CD4+ T cells
markedly increased the expression of CD32 either at the cell surface or intracellularly.
Analysis of CD32 mRNA transcripts in activated CD4+ T cells revealed the presence
of both, the stimulatory FcγRIIa (CD32a) and the inhibitory FcγRIIb (CD32b) isoforms of
CD32, being the CD32a:CD32b mRNA ratio∼5:1. Consistent with this finding, we found
not only that CD4+ T cells bind aggregated IgG, used as an IC model, but also that CD32
ligation by specific mAb induced a strong calcium transient in CD4+ T cells. Moreover,
we found that pretreatment of CD4+ T cells with immobilized IgG as well as cross-linking
of CD32 by specific antibodies increased both, the proliferative response of CD4+ T cells
and the release of a wide pattern of cytokines (IL-2, IL-5, IL-10, IL-17, IFN-γ, and TNF-α)
triggered by either PHA or anti-CD3 mAb. Collectively, our results indicate that ligation of
CD32 promotes the activation of CD4+ T cells. These findings suggest that ICs might
contribute to the perpetuation of chronic inflammatory responses by virtue of its ability
to directly interact with CD4+ T cells through CD32a, promoting the activation of T cells
into different inflammatory profiles.
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INTRODUCTION
Receptors for the Fc portion of IgG (FcγRs) are widely express in immune cells and mediate a large
array of effector and immunomodulatory mechanisms that influence both innate and adaptive
responses (1). FcγRs are classified into two main types that include different members. Type I
FcRs belong to the immunoglobulin receptor superfamily and are represented by the canonical Fcγ
receptors, including FcγRI, FcγRII, and FcγRIII. Type II FcRs belong to the family of C-type lectin
receptors, and include CD209 (DC-SIGN) and CD23 (2). Based on the signaling motifs expressed
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in the cytoplasmic domains, type I FcγRs are classified
as stimulatory or inhibitory receptors, which are associated
with immunoreceptor tyrosine activation motifs (ITAM) or
immunoreceptor tyrosine inhibition motifs (ITIM), respectively
(1, 3, 4). Stimulatory type I receptors include FcγRI (CD64),
FcγRIIa (CD32a), FcγRIIc (CD32c), and FcγRIIIa (CD16),
while inhibitory type I receptors only include FcγRIIb (CD32b)
(5). Activating FcγRs signal through an ITAM motif that
is either present in their intracytoplasmic domain or in
associated signaling subunits, such as the FcRγ chain. These
ITAM-containing structures allow FcγRs, once aggregated by
multimeric ligands, to stimulate signaling cascades via SRC and
SYK kinases promoting cell activation. The inhibitory receptor
FcγRIIb possesses instead an ITIM motif in its intracytoplasmic
domain, which allows this receptor to recruit the SHIP1
phosphatase that counteracts the signaling cascades initiated by
activating FcγRs. Therefore, the co-expression of these divergent
receptors, which share almost identical ligand-binding domains,
establishes a threshold of cell activation (3, 6–8).
The expression pattern and the function of type I FcγR have
been well characterized in innate immune cells and B cells (2, 8,
9). By contrast, the expression and function of CD32 in CD4+
T cells remain controversial. The most cited reviews in the field
assume that CD4+ T cells do not express FcγRs (1, 10, 11),
however, contrasting observations have been published. It has
been reported that resting CD4+ T cells do not express CD32
(12–14), while other studies have shown that a minor fraction
of resting CD4+ T cells (1–5%) actually expresses CD32 (15,
16). It has also been reported that activation of CD4+ T cells
promotes an increased expression of CD32 (17, 18). Moreover,
early studies have claimed that more than 80% of resting CD4+
T cells expresses high amounts of CD32 as an intracellular pool
(18–20). Interestingly, recent observations suggested that CD32
is a marker of a CD4+ T cell population that contains an
HIV reservoir harboring replication-competent proviruses (14),
however this finding remains controversial (16, 21).
Immune complexes (ICs) are the natural ligands of low affinity
FcγRs (1). High levels of ICs are found in chronic viral infections
and autoimmune diseases (22). Moreover, a large body of
evidence suggest that ICs play a key role not only in the induction
of tissue injury, but also in the promotion of T cell responses (23–
28). Themechanisms underlying the ability of ICs to promote the
stimulation of T cells have not been clearly defined yet. However,
it is usually assumed that they are related to the ability of ICs to
interact with FcγRs expressed bymacrophages and dendritic cells
improving antigen presentation to both CD4+ and CD8+ T cells
(27, 28). Interestingly, the enhanced antigen immunogenicity
conferred by ICs has been adopted as strategy to improve the
Abbreviations: aCD3/aCD28, anti-CD3 and anti-CD28 stimulation; aIgG,
aggregated IgG; ART, antiretroviral treatment; cIgG, coated IgG; Fab’2, F(ab’)2
fragment goat anti mouse IgG; FBS, Fetal Bovine Serum; FcγRs, Fc γ receptors;
ICs, Immune Complexes; ITAM, immunoreceptor tyrosine activation motifs;
ITIM, immunoreceptor tyrosine inhibition motifs; mAb, monoclonal antibody;
PBMCs, Peripheral Blood Mononuclear Cells; PBS, Phosphate Buffered Saline;
PHA, phytohemagglutinin; STAT, Signal transducer and activator of transcription;
TCR, T cell receptor.
therapeutic efficiency of vaccines in experimental models of viral
infectious diseases (27, 29, 30).
Here, we showed that a minor fraction of resting CD4+ T cells
express cell surface CD32. Activation of CD4+ T cells promoted
a marked increase in the expression of CD32 either at the cell
surface or intracellularly. Analysis by qRT-PCR on activated
CD4+ T cells revealed the presence of mRNA transcripts
for both, the stimulatory FcγRIIa (CD32a) and the inhibitory
FcγRIIb (CD32b) isoforms, being the CD32a:CD32bmRNA ratio
∼5:1. Consistent with this finding, we found that cross-linking
of CD32 by immobilized IgG or specific mAb directed to CD32
enhanced both, the proliferative response and a wide pattern of
cytokines by CD4+ T cells stimulated by PHA or anti-CD3 mAb.
Overall, our observations suggest that ICs might perpetuate the
chronic inflammatory response in patients with autoimmunity
and/or chronic viral infections, not only by stimulating innate
immune cells, but also by directly interacting with CD4+ T cells
via CD32a.
MATERIALS AND METHODS
Subjects
Buffy coat was obtained from 1 unit of blood collected from
45 donors (average 34 years, range 25–42 years), and processed
immediately after volunteer’s donations. None of the donors
had any hereditary disorders, hematologic abnormalities, or
infectious diseases. The local ethics committee has approved
this study and informed consent was obtained from all
donors.
Peripheral Blood Mononuclear Cell
(PBMCs) Isolation
PBMCs were obtained from buffy coats by Ficoll-Hypaque
gradient centrifugation (GE Healthcare Life Sciences).
Monocytes and CD4+ T Cell Isolation
Monocytes and/or CD4+ T cells were enriched from buffy coats
by using the RosetteSep human monocyte and/or CD4+ T
cells enrichment cocktails (Stem Cell Technologies) respectively,
following themanufacturer’s protocols. The purity determined by
flow cytometry was always >97%.
Cell Sorting
Both CD32+CD4+ and CD32-CD4+ T cell subsets were
purified by cell sorting with a FACSAria Fusion flow cytometer
(BD Biosciences). Briefly, previously activated PBMCs were
stained with anti-CD3 PerCP, anti-CD4 APC, and CD32 PE-
Cy7 monoclonal antibodies (mAbs, all from Biolegend) and
sorted yielding the following subpopulations CD4+CD32+ T
cells and CD4+CD32- T cells. Cells were collected into RPMI
1640 medium containing 50% FBS and washed twice prior to
further studies. The purity determined by flow cytometry was
always >99% for each subset. Cells were resuspended in TRIzol
reagent (Thermo Fisher) and used for qRT-PCR.
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Flow Cytometry
Freshly isolated or in vitro-cultured cells were stained with anti-
CD3, CD4, CD8, CD14, CD19, CD25, HLA-DR, PD-1, and Tim-
3 mAb (all from Biolegend). Staining of CD32 was performed
by using two different anti-human CD32 mAb: FUN.2 clone
(mouse anti-human CD32 PE or PECy7 conjugated, Biolegend)
and IV.3 clone (mouse anti-human CD32 purified antibody,
Stem Cell Technologies) that was revealed with a secondary PE
goat Fab2 anti-mouse IgG (DAKO). Intracellular detection of Ki-
67 antigen with anti-Ki-67 antibody was performed using fixed
and permeabilized cells following the manufacturer’s instructions
(BD Biosciences). Control samples were incubated with an
isotype-matched antibody. For the determination of CD32
expression, PE and/or PE-Cy7 mouse IgG2b kappa (Biolegend)
were included as isotype controls, using a threshold value ≤0.2
in all cases. When CD32 was determined by using unconjugated
IV.3 clone, a purified mouse IgG2b kappa (Biolegend) was
used as isotype control followed by a secondary PE anti-mouse
antibody. Dead cells were excluded by forward and side scatter
characteristics. Statistical analyses were based on at least 100,000
events gated on the population of interest. The data were acquired
using a FACSCanto II (Becton Dickinson) and analyzed with
FlowJo software.
Fluorescence Microscopy
Briefly, purified cells were incubated with monoclonal anti-
CD32 Alexa Fluor 647 and anti-CD4 Alexa Fluor 488 or
anti-CD14 Alexa Fluor 488 as indicated (all from Biolegend).
Then, cells were washed twice and allowed to adhere on
polylysine-coated coverslips. After which, cells were fixed with
4% paraformaldehyde in Phosphate Buffered Saline (PBS) for
12m at 4◦C, washed twice and treated with 10mM glycine
for 10m at room temperature. The coverslips mounted with
DAPI Fluoromount-G (SouthernBiotech) were studied in a
Nikon Eclipse Ti-S L100 fluorescence microscope using a Plan
Apochromat 100× 1.40 NA oil immersion objective.
PBMCs Culture
PBMCs (1 × 106/ml) were stimulated with IL-2 (20 ng/ml,
Peprotech), coated anti-CD3 (aCD3, 10µg/ml, Beckman
Coulter) plus soluble anti-CD28 (aCD28, 1 mg/ml, BD
Biosciences), or unstimulated, and cultured for 36 h in medium
RPMI 1640 (Gibco) supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Natocor), 2mM L-glutamine (Gibco),
100 U/ml penicillin (Gibco), and 0.1 mg/ml streptomycin
(Gibco). In some experiments, cells were treated with
phytohemagglutinin (PHA, 4µg/ml; Sigma-Aldrich) and
cultured for 36 h. After that, cells were washed twice and
analyzed by flow cytometry.
Real-Time Quantitative RT-PCR
Total RNA was extracted using TRIzol reagent following
manufacturer’s instructions. Subsequently, RNA was treated with
RQ1 RNAse-free DNAse (Promega) and reverse transcripted
using M-MLV Reverse Transcriptase (Sigma-Aldrich). PCR
analysis for both, CD32a (FcγRIIa) and CD32b (FcγRIIb)
isoforms was performed with a real-time PCR detection system
(StepONE-Plus Applied Biosystems) using 5 × HOT FIREPol R©
EvaGreen R© qPCR Mix Plus (ROX) (Solis BioDyne Corp)
as a fluorescent DNA-binding dye. GAPDH was used as
housekeeping gene. The amplification protocol was as follows: 1
cicle at 95◦C for 10m and 40 cycles of denaturation at 95◦C for
15 s, annealing at 56◦C for 15 s and extension at 72◦C for 1m. The
melting curve was also performed. Each sample was evaluated by
triplicate.
The following primer sets were used: FcγRIIa forward
primer, 5′-ATCATTGTGGCTGTGGTCATTGC-3′ and reverse
primer, 5′- TCAGGTAGATGTTTTTATCATCG-3′; and
FcγRIIb forward primer, 5′- GGGATCATTGTGGCTGTG-3′
and FcγRIIb reverse primer, 5′-ATTAGTGGGATTGGCTG-3′.
GAPDH forward primer, 5′-GAGTCAACGGATTTGGTCGT-3′
and reverse primer 5′-TTGATTTTGGAGGGATCTCG-3′.
Primer sets yielded a single product of the correct size.
As a source of cDNA for standard curves to which all
samples were normalized (calibrator), monocytes were isolated as
previously described. Standard curves and relative quantification
was performed as previously published (31). In short, the
threshold cycle (CT) values, determined by the StepONE Plus
software v2.3, were used to calculate and plot a linear regression
curve to evaluate the quality of the standard curve. The slope of
this line was used to determine the efficiency of the reaction (E).
From the CT’s and the efficiencies obtained, the normalized value
was calculated with the following formula: ET
CpT(C)−CpT(S):ER
CpR(C)−CpR(S), in which ET is the efficiency of the PCR of the
target gene (FcγRIIa or FcγRIIb2); ER, the efficiency of the PCR
of the reference gene (GAPDH); CpT(C), the measured CT of
the target gene determined for standard or calibrator (FcγRIIa or
FcγRIIb of one selected monocyte sample for all measurements);
CpT(S), the measured CT of the target gene determined for the
sample (donor of interest); CpR(C), the measured CT of the
reference gene of the calibrator or standard; and CpR(S), the
measured CT of the reference gene of the sample.
Ligation of CD32
CD32 was cross-linked in purified CD4+ T cells by using two
different approaches:
1- Ligation with coated IgG (cIgG): We immobilized IgG on
plastic plates, as described (32). Human IgG (500µg/ml,
Sigma-Aldrich) was added to each well of a 48 multiwell
plate (GBO). After overnight incubation, plates were washed
3 times with PBS to yield immobilized IgG. Purified CD4+ T
cells (1× 106/ml) were seeded on cIgG overnight.
2- Ligation with specific anti-CD32 mAb: Purified CD4+ T cells
(1 × 106/ml) were preincubated for 30m with anti-CD32
mAb (30µg/ml, clone IV.3; Stem Cell Technologies) and
then stimulated by the addition of F(ab′)2 fragment goat anti
mouse IgG (Fab’2, 50µg/ml; Jackson ImmunoResearch) for
additional 30min. Afterwards, cells were seeded on uncoated
plates overnight.
After CD32 ligation by one of the two aforementioned
approaches, cells were stimulated with suboptimal doses of PHA
(0.5µg/ml) or anti-CD3 coated beads (0.025µg/ml, Miltenyi
Biotec) and cultured during 5 d. As controls, CD4+ T cells
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were added to uncoated plates and stimulated with PHA or anti-
CD3 coated beads, according to the experiment. The proliferative
response and the cytokine levels were analyzed by flow cytometry
and ELISA, respectively.
Neutralization Assay
To block the CD32 receptor expressed by CD4+ T cells, cells
were incubated with a blocking anti-CD32 mAb (30µg/ml, clone
IV.3) before being exposed to cIgG (IV.3 plus cIgG). An isotype-
matched antibody was used as a control.
Binding of Heat-Aggregated IgG (aIgG)
IgG aggregates (aIgG) were prepared by heating human IgG
(25 mg/ml) for 12m at 63◦C. Then, aIgG was centrifuged at
10,000 g for 5m and the precipitate was discarded. Resting or
activated purified CD4+ T cells were incubated with different
doses of aIgG (50, 100, or 400µg/ml, as indicated), or serum
free-medium for 2 h at 37◦C. Then, cells were washed three times
and stained with biotinylated anti-human IgG Fc (Biolegend) for
30m at 4◦C followed by streptavidin PerCP and anti-CD4 V500.
Binding of aIgG was analyzed by flow cytometry. In blocking
experiments, cells were pretreated with the blocking antibody
IV.3 clone (30µg/ml) for 30m at 4◦C, before the addition of aIgG
(IV.3 plus aIgG).
Calcium Mobilization Assay
CD32-triggered calcium transients were analyzed by flow
cytometry on purified CD4+ T cells using Fluo-3,AM probe
(Molecular Probes, Thermo Fisher). Briefly, 1 × 106 resting
CD4+ T cells were stained with anti-CD4 mAb APC. After
washing twice, cells were treated with 5µM Fluo-3,AM for 20m
at 37◦C. Then, the sample was immediately loaded onto the
flow cytometer for calcium baseline measurement during 30 s.
Afterward, the purified anti-CD32 mAb (IV.3 clone, 30µg/ml)
was added and calcium measurement was performed for other
30 s. Subsequently, the cells were incubated at 37◦C for 15m.
After this time, Fab′2 (50µg/ml) was added and calcium
mobilization was measured immediately and incubated at 37◦C
for another 60 s. Finally, the fluorescence was recorded during an
additional period of 60 s. As a positive control, we treated cells
with ionomycin (Sigma-Aldrich). A time-based gate was used for
the analysis in gated CD4+ T cells.
STAT5 and STAT6 Phosphorylation
Purified CD4+ T cells (1 × 106) were cultured in the presence
of cIgG (500µg/ml) or IV.3 (30µg/ml) plus cIgG for 18 h. Then,
cells were re-stimulated with PHA (0.5µg/ml) and cultured for
3 d. After this period, cells were fixed and permeabilized (BD
Biosciences) according to the manufacturer’s protocols. Cells
were washed twice with PBS and stained with anti-CD3 FITC and
anti-STAT 5 (pY694) Alexa Fluor 647 or anti-STAT6 (pTyr641)
Alexa Fluor 647, for 30m at room temperature. Cells were then
analyzed on a BD FACS Canto II flow cytometer.
ELISA
Levels of IL-2, IL-5, IL-10, IFN-γ, TNF-α (BD Biosciences), and
IL-17 (Biolegend) were quantified in cells supernatants by ELISA
following manufacturer’s recommendations.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6
software. Two groups were compared using theWilcoxon signed-
rank test orMann–Whitney t-test as appropriated. Three ormore
groups were compared using the Kruskall–Wallis test followed
by Dunn’s multiple comparison tests. A p < 0.05 was considered
statistically significant.
RESULTS
Resting CD4+ T Cells Express CD32
In a first set of experiments, we explored the expression of CD32
in resting CD4+ T cells by using two different anti-CD32 mAbs
(FUN.2 and IV.3 clones). CD32 expression was also analyzed
on monocytes, B cells, and CD8+ T cells. As described (33–35),
monocytes and B cells showed a high expression of CD32, by
contrast only a minor fraction of CD8+ T cells and CD4+ T cells
expressed CD32. In fact, we found that ∼2.4% ± 0.4 of CD4+ T
cells were shown to be positive for the expression of CD32 (n =
18; Figures 1A–C). We then analyzed the cytoplasmic expression
of CD32 in CD4+ T cells. Results in Figures 1D,E show that
∼8.5% ± 1.9 of permeabilized cells expressed CD32 (n = 9),
indicating that CD4+ T cells store an intracellular pool of this
receptor.
Increased Expression of CD32 in Activated
CD4+ T Cells
Next, we examinedwhether T cell activation was able tomodulate
CD32 expression. PBMCs were stimulated with IL-2 or with
antibodies directed to CD3 and CD28 for 18 or 36 h. Then, the
expression of CD32 was analyzed. Treatment with aCD3/aCD28
antibodies markedly increased cell surface expression of CD32
at either 18 or 36 h of culture while IL-2 induced no increase
of CD32 expression (Figures 2A,B). We also observed that
activation of CD4+ T cells by aCD3/aCD28 antibodies resulted
in an increased pool of cytoplasmic CD32 (Figures 2C,D).
Activation of CD4+ T cells by PHA also promoted an
increased expression of CD32 (Figures 2E,F). Because the
expression of CD32 was increased during CD4+ T cell activation,
we analyzed whether CD32 expression was associated with the
induction of T cell activation markers. Results in Figure 2G
show that the subpopulation of CD32+ CD4+ T cells was
enriched not only in the expression of activation markers
such as CD25 and HLA-DR, but also in the expression of
the inhibitory receptors PD-1 and Tim-3, which are usually
associated with an exhausted CD4+ T cell phenotype (36).
Further experiments were performed to evaluate the relative
expression of CD32 isoforms (CD32a and CD32b) by qRT-
PCR in sorted CD32+CD4+ and CD32-CD4+ T cell subsets,
after activation with aCD3/aCD28 antibodies. We found that the
mRNA levels for CD32a were significantly higher compared with
CD32b, being the CD32a:CD32b mRNA ratio ∼5:1 in both cell
subsets (n = 7, Figure 2H). On the other hand, and consistent
with the higher expression of CD32 observed in activated cells,
we found that cell activation also resulted in an increased ability
of CD4+ T cells to bind aIgG, in a dose-dependent mode
(Figures 3A,B). As expected, binding of aIgG was prevented by
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FIGURE 1 | Analysis of CD32 expression in resting CD4+ T cells. (A) Representative dot plot of CD32 cell surface expression in monocytes (CD14+), B cells
(CD19+), CD8+ and CD4+ T cells from a healthy adult donor using two different anti-CD32 mAb (FUN.2 and IV.3 clones) analyzed by flow cytometry. Surface isotype
control labeling was set to stringent criteria. Results are expressed as percentages on PBMCs. (B) Frequency of CD32+ cells on gated CD4+ T cells from healthy
adults using the FUN.2 clone mAb by flow cytometry. (C) Fluorescence microscopy of CD32 expression in purified CD4+ T cells and monocytes (green: CD4 or
CD14, red: CD32). Nuclear counterstain with DAPI was used. Representative images are shown at x300. (D) Representative dot plot of cell surface and cytoplasmic
CD32 expression in permeabilized resting CD4+ T cells. Surface and cytoplasmic isotype controls are shown. (E) Frequency of cell surface and cytoplasmic CD32
expression on resting CD4+ T cells. Results are expressed as percentages on CD4+ T cells. Representative experiments are shown in (A,C,D). Mean ± SEM of n
donors are shown in (B) (n = 18) and (E) (n = 9). *p < 0.05. Wilcoxon matched-pairs signed rank test was used for analysis in (E).
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FIGURE 2 | Activation of CD4+ T cells results in an increased expression of CD32. (A,B) PBMCs were cultured with medium (controls), IL-2 (20 ng/ml) or immobilized
anti-CD3 (10µg/ml) plus soluble anti-CD28 (1 mg/ml) (aCD3/aCD28) antibodies, during 18 or 36 h. The frequency of CD32+CD4+ T cells was analyzed by flow
cytometry. (A) Representative dot plots of cell surface expression of CD32 in CD4+ T cells analyzed at 36 h of culture. Results are expressed as percentages on total
lymphocytes. (B) Frequency of CD32+ cells on gated CD4+ T cells at 18 and 36 h of culture. (C–F) PBMCs were activated with either aCD3/aCD28 antibodies (C,D)
or PHA (4µg/ml, E,F) for 36 h. Then, cell surface or intracellular expression of CD32 was analyzed. Cell surface expression of CD25 was also assessed. Cytoplasmic
isotype control is shown in (C,E). (G) Cell frequency of the different markers analyzed in CD32+CD4+ and CD32-CD4+ T cells. Results are expressed as percentage
on each CD4+ T cell subset analyzed. (H) CD32a/CD32b mRNA ratio in activated CD32-CD4+ and CD32+CD4+ T cell subsets analyzed by qRT-PCR.
Representative experiments are shown in (A,C,E). Mean ± SEM of n donors are shown in (B) (n = 7), (D) (n = 7), (F) (n = 7), (G) (n = 8), and (H) (n = 7). *p < 0.05,
**p < 0.01, ****p < 0.0001. Kruskal–Wallis test followed by Dunn’s multiple comparison was used for analysis in (B). Wilcoxon matched-pairs signed rank test was
used for analysis in (D,F,G,H).
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FIGURE 3 | CD4+ T cells bind aIgG. (A) Resting or activated purified CD4+ T cells were incubated with aIgG (400µg/ml) or serum-free medium for 2 h. Then, cells
were washed and the binding of aIgG was analyzed by flow cytometry. (B) Activated CD4+ T cells were incubated with increasing concentrations of aIgG (50, 100,
and 400µg/ml) or serum-free medium. Data show the percentage of aIgG+CD4+ T cells. (C,D) Activated CD4+ T cells were treated with or without an anti-CD32
blocking antibody (IV.3 clone, 30µg/ml) during 30m. After washing, cells were incubated with 100µg/ml of aIgG or serum-free medium. (C) Representative
histograms of aIgG percentage are shown. (D) Percentage of aIgG+CD4+ T cells is shown. Representative experiments are shown in (A,C). Mean ± SEM of n
donors are shown in (B) (n = 8) and (D) (n = 8). **p < 0.01, ***p < 0.001, ****p < 0.0001. Kruskal–Wallis test followed by Dunn’s multiple comparison was used for
analysis in (B). Mann–Whitney test was used for analysis in (D).
the anti-CD32 blocking IV.3 mAb (14.1% ± 2.2 vs. 3.4% ± 0.6,
for aIgG and IV.3 plus aIgG, respectively, p < 0.01, n = 8;
Figures 3C,D).
Ligation of CD32 Promotes the Activation
of CD4+ T Cells
Ligation of CD32 has shown to induce calcium signaling in
myeloid cells and platelets (37, 38). To analyze the functionality
of CD32, we first analyzed its ability to induce calcium transient
in CD4+ T cells. In these experiments, cells were preincubated
with the IV.3 mAb and then treated with a Fab’2 polyclonal goat
anti-mouse IgG (39). Results in Figure 4A (upper panel) show
that CD32 ligation caused the induction of a strong calcium
transient.
We then analyzed whether CD32 ligation was able to promote
the proliferation of CD4+ T cells. In these experiments, isolated
CD4+ T cells were stimulated, or not, with cIgG or IV.3 plus
a Fab′2 polyclonal goat anti-mouse IgG (IV.3 plus Fab′2) for
18 h. Then, cells were re-stimulated with a suboptimal dose of
PHA (0.5µg/ml) and cultured during 5 d. The proliferative
response was analyzed by studying the expression of the Ki-
67 antigen as a proliferation marker. We found that ligation
of CD32 does not induce proliferation of CD4+ T cells (data
not shown), but significantly increased the proliferative response
induced by PHA. As expected, pretreatment of CD4+T cells with
the blocking IV.3 mAb significantly prevented the enhancing
effect induced by cIgG on the proliferation of CD4+ T cells
(Figures 4B,C). No proliferation was observed in cells treated
only with IV.3 or a secondary goat Fab2 anti-mouse IgG,
compared with those cells cultured in medium alone (data not
shown). Consistent with these findings, we found that CD32
ligation also stimulated the proliferative response of CD4+ T
cells triggered by beads coated with anti-CD3 mAb (28.2% ±
7.1 and 3.5% ± 0.9, for CD4+ T cells pretreated, or not, with
cIgG, respectively, p < 0.01; n = 6). Moreover, this enhancing
effect was significantly inhibited in presence of the mAb IV.3
(Figures 4D,E).
Not only the proliferation, but also the production of a wide
pattern of cytokines was stimulated by CD32 ligation in CD4+
T cells cultured with suboptimal doses of PHA. However, the
two different approaches for CD32 ligation displayed a different
stimulating ability (Figure 5A). Cross-linking of IV.3 with a
Fab′2 goat anti-mouse IgG (IV.3 plus Fab′2) resulted in a strong
enhancement in the production of IL-2 (1738.0 pg/ml ± 490.6
vs. 10.6 pg/ml ± 3.8, p < 0.001), IL-5 (267.9 pg/ml ± 57.9 vs.
17.9 pg/ml± 11.0, p < 0.001), IL-10 (793.1 pg/ml± 15.8 vs. 36.7
Frontiers in Immunology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 2814
Holgado et al. CD32 and CD4+ T Cells
FIGURE 4 | Stimulation through CD32 promotes the expansion of CD4+ T cells activated by suboptimal doses of different stimuli. (A) Purified CD4+ T cells labeled
with fluo-3,AM fluorescent probe were treated with an anti-CD32 mAb (IV.3 clone) for 15m. Then a F(ab′)2 fragment goat anti mouse IgG was added to induce the
cross-linking of bound IV.3 mAb. Induction of cytosolic calcium transients was analyzed by flow cytometry at three different times: before and after addition of IV.3 and
after stimulation with Fab′2 (upper panel). Cells were treated with ionomycin as a positive control (lower panel). A representative experiment is shown (n =5).
Geometric mean of fluo-3,AM vs. time is depicted. (B–E) Purified CD4+ T cells (1 × 106) were cultured in the presence of medium (control), cIgG or IV.3 plus a Fab′2
antibody directed to mouse IgG, for 18 h. When IV.3 was used as blocking mAb, cells were pretreated with IV.3 clone, before being exposed to cIgG. Then, cells were
stimulated with a suboptimal concentration of PHA (0.5µg/ml, B,C) or anti-CD3 coated beads (0.025µg/ml, D,E) and cultured for 5 d. Proliferative response was
evaluated by using Ki-67 staining. (B–D) Representative dot plots of CD4 and Ki-67 staining are shown. Results are expressed as cell percentages on gated CD4+ T
cells. (C–E) Percentage of Ki-67+CD4+ T cells analyzed by flow cytometry. Representative experiments are shown in (B,D). Mean ± SEM of n donors are shown in
(C) (n = 10) and (E) (n = 6). *p < 0.05, **p < 0.01. Kruskal–Wallis test followed by Dunn’s multiple comparison was used for analysis in (C,E).
pg/ml± 11.8, p< 0.0001), IFN-γ (4443.0 pg/ml± 1218 vs. 1132.0
pg/ml ± 591.1, p < 0.05), and TNF-α (414.6 pg/ml ± 147.0 vs.
12.3 pg/ml ± 4.0, p < 0.001), compared with control cells (n =
10). There was also a non-significant increase in the production
of IL-17. No cytokine secretion was detected in cells treated only
with IV.3 or a secondary goat Fab2 anti-mouse IgG (data not
shown). On the other hand, exposure of CD4+ T cells to cIgG did
not increase IL-2 levels, but significantly enhanced the secretion
of IL-5 (77.9 pg/ml ± 25.3; p < 0.01), IL-10 (142.9 pg/ml ± 33.6;
p < 0.05), IFN-γ (4954.0 pg/ml ± 772.8; p < 0.001), and TNF-
α (59.1 pg/ml ± 16.9; p < 0.01), compared with control cells.
Pretreatment of CD4+ T cells with the IV.3 mAb significantly
inhibited the stimulatory effect of cIgG on the production of IL5,
IFN-γ, and TNF-α (Figure 5A).
Similar findings were observed in CD4+ T cells upon
stimulation with anti-CD3 coated beads. Exposure of CD4+ T
cells to cIgG significantly increased the secretion of IL-5 (338.1
pg/ml ± 90 vs. 75.7 pg/ml ± 37.4; p < 0.01), IL-17 (59.1 pg/ml
± 16.4 vs. 13.2 pg/ml ± 7.0; p < 0.01), compared with control
cells. It also promoted the secretion of IL-2 (208.5 pg/ml ± 93.8
vs. 35.8 pg/ml ± 18.6), IL-10 (329.2 pg/ml ± 69.4 vs. 130.4
pg/ml ± 46.2), IFN-γ (27,323 pg/ml ± 8285 vs. 10,126 pg/ml ±
5704), and TNF-α (360.2 pg/ml ± 123.3 vs. 130.8 pg/ml ± 36.2)
compared with control cells, even this enhancing effect did not
reach statistical significance (n = 6). As expected, pretreatment
of CD4+ T cells with the IV.3 mAb significantly inhibited the
stimulatory effect of cIgG on the production of IL5, IL-10, IL-17,
IFN-γ, and TNF-α (Figure 5B).
IL-2 supports the proliferation of CD4+ T cells being
the activation of STAT5 one of the earliest events in IL-2
signaling through the high affinity IL-2 receptor (40). Results in
Figures 5C,D show that cIgG promoted STAT5 phosphorylation
in CD4+ T cells cultured with suboptimal concentrations of
PHA (9.4% ± 3.2 vs. 4.4% ± 1.3, for cIgG treated vs. untreated
cells, p < 0.05). Moreover, we found that cIgG also enhanced
the phosphorylation of STAT6, which is the main transcription
factor responsible for the development of Th2 cells (41) (38.6%
± 14.5 vs. 10.5% ± 4.6, for cIgG treated vs. untreated cells, p
< 0.05). As expected, pretreatment with the blocking IV.3 mAb
significantly prevented the stimulatory effect induced by cIgG on
the phosphorylation of both, STAT5 and STAT6 (Figure 5E,F,
n= 5).
DISCUSSION
The expression and function of FcγRs in innate immune cells
and B cells have been clearly defined (2, 9, 10). Although it
is generally assumed that T cells do not express FcγRs (8, 12,
42) a more detailed analysis of early published studies shows
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FIGURE 5 | Stimulation through CD32 promotes the release of cytokines in CD4+ T cells activated by suboptimal doses of different stimuli. (A,B) Purified CD4+ T
cells (1 × 106) were cultured in the presence of medium (control, white bar), cIgG (black bar) or IV.3 plus a Fab′2 antibody directed to mouse IgG (striped bar), for
(Continued)
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FIGURE 5 | 18 h. When IV.3 was used as blocking mAb, cells were pretreated with IV.3 clone, before being exposed to cIgG (gray bar). Then, cells were stimulated
with a suboptimal concentration of PHA (0.5µg/ml, A) or anti-CD3 (0.025µg/ml, B) and cultured for 5 d. Levels of cytokines were quantified in the culture supernatant
by ELISA. (C–F) Purified CD4+ T cells (1 × 106) were cultured in the presence of medium or cIgG for 18 h. When IV.3 was used as blocking mAb, cells were
pretreated with IV.3 clone, before being exposed to cIgG. Then, cells were stimulated with a suboptimal concentration of PHA (0.5µg/ml) and cultured for 3 d. STAT5
(C,D) and STAT6 (E,F) phosphorylation was analyzed by flow cytometry. Results are expressed as percentage on CD4+ T cells. Representative experiments are
shown in (C,E). The mean ± SEM of n experiments is shown in (A) (n = 10), (B) (n = 6), (D) (n = 5), and (F) (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. Mann–Whitney test was used for analysis in (A,B). Kruskal–Wallis test followed by Dunn’s multiple comparison was used for analysis in (D,F).
contradictory findings (17–19). In this study, we found not only
that a minor fraction of resting CD4+ T cells expresses CD32,
but also that T cell activation induces a marked up-regulation
of CD32 expression in either the cell surface or the cytoplasmic
compartment. The role of CD32, if any, in determining the
function of CD4+ T cells remains undefined. Here we reported
that, contrasting with the inhibitory effect of CD32 in B cell
responses (3, 43), it promotes the activation of CD4+ T cells.
Our observations indicating that a small percentage of resting
CD4+ T cells expresses cell surface CD32 are in agreement with
those data recently reported by Martin et al. (16) in studies
directed to analyze the role of CD32+CD4+ T cells as viral
reservoirs in HIV-infected patients. Moreover, in accordance
with Sandilands et al. (19), we also found that resting CD4+ T
cells express a cytoplasmic pool of CD32. However, while these
authors reported that more than 90% of resting CD4+ T cells
stores an intracellular pool of CD32, we found that only ∼9% of
resting CD4+ T cells contain a cytoplasmic pool of CD32. The
reasons underlying this discrepancy are unclear. On the other
hand, and in agreement with early works (17, 18), we detected
that activation of CD4+ T cells increases cell surface expression
of CD32, reaching a peak at 36 h of culture. We also found that
CD32 expressing CD4+ T cells displayed an activated phenotype
characterized by the expression of activation markers such as
CD25 and HLA-DR as well as by the expression of the inhibitory
receptors PD-1 and Tim-3, which are usually associated with
an exhausted CD4+ T cell phenotype. Accordingly, with these
findings, we observed that activated CD4+ T cells bind higher
amounts of aIgG compared with resting cell. Our results showing
that concentrations of aIgG as high as 100µg/ml were unable to
saturate CD32 binding capacity are consistent with the fact that
CD32 is a low- affinity FcγR.
It has long been known that IgG ICs suppress humoral
immunity. This effect is mediated through the interaction of
the Fc fragment of IgG antibodies with the only FcγR isoform
expressed by B cells, FcγRIIb. In fact, cross-linking of FcγRIIb
with the B cell receptor has shown to increase the threshold
for B cell activation, inhibiting antibody production (3, 43, 44).
Interestingly, our findings revealed for the first time that cross-
linking of CD32 efficiently promoted the activation of CD4+
T cells stimulated by either suboptimal doses of PHA or anti-
CD3 mAb. Our results showing that ligation of CD32 promotes
the activation of CD4+ T cells suggest that CD32a is the
predominant type of FcγRII expressed in this cell population.
The similarity of the extracellular domains of CD32b and CD32a
does not enable the differentiation of these receptors by flow
cytometry because there are no commercially available antibodies
that can distinguish between them. The present study provides
evidence indicating the presence of both CD32 mRNA isoforms
in activated CD4+ T cells, being CD32a the predominant one.
In fact, we found that activation of CD4+ T cells resulted in the
expression of both CD32a and CD32b transcripts in a ratio of 5:1,
respectively.
Ligation of CD32 induced by seeding CD4+ T cells on
immobilized IgG or by treatment with anti-CD32 mAbs
promoted neither cell proliferation nor cytokine production by
CD4+ T cells. However, both stimuli significantly enhanced
the proliferative response and the production of a wide array
of cytokines by CD4+ T cells treated with suboptimal doses
of PHA or anti-CD3 mAb. We found a higher production of
cytokines associated with the development of Th1 (IL-2, IFN-γ,
and TNF-α), Th2 (IL-5), and Th17 (IL-17) profiles, suggesting
that CD32 ligation does not promote a particular signature in
CD4+ T cells. Because ICs are the most important ligands for
FcγRs, our observations might be relevant in those disorders
associated with the presence of high levels of circulating ICs,
such as chronic infections (45–47), autoimmune diseases (48–
51) and cancer (52–54). Our results suggest that ICs might
promote the development of inflammatory responses, by acting
directly on CD4+ T cells via CD32a. Moreover, our results
could contribute to better explain why antigens contained in
ICs promote a stronger T cell responses compared with non-
complexed antigens, a phenomenon usually attributed to the
ability of ICs to stimulate antigen presentation through major
histocompatibility complex class II and class I molecules (27–
30). Further studies are required to confirm both, the ability of
ICs to activate CD32 in presence of the high concentrations of
monomeric IgG found in plasma and the in vivo relevance of our
observations.
It should be note that the ability of ICs to modulate the
function of CD4+ T cells could be related not only to the
expression of CD32, but also to the expression of CD16 (FcγRIII).
Early studies showed the expression of CD16 in a small number
of peripheral T cells in healthy individuals (12, 55). Moreover,
more recent studies performed by Chauhan and coworkers (13,
56–58) reported that CD4+ T cell activation leads to the up-
regulation of CD16 expression. In a first paper, the authors
showed that ligation of CD16 in CD4+ T cells by ICs induces
a co-stimulatory signal promoting IFN-γ production (56). In a
second study, they reported that ICs isolated from systemic lupus
erythematosus patients interact with CD16 expressed by CD4+ T
cells and induce Syk phosphorylation, providing a co-stimulatory
signal to T cells in the absence of CD28 signal. This mechanism
was shown to be able to promote the development of Th1 and
Th17 cells (57). Finally, the authors reported that stimulation
of CD4+ T cells by ICs induced, not only the up-regulation of
endosomal toll-like receptors (TLRs), but also the accumulation
of TLR9 on the cell surface (13).
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Overall, our results suggest that CD32 ligation promoted
CD4+ T cell activation. Whether CD16 might acts in concert
with CD32 to induce the activation of CD4+ T cells remains
to be addressed. Because autoimmune diseases are usually
associated with the formation and tissue deposition of immune
complexes (42), we hypothesize that they might contribute to
tissue damage, not only by activating inflammatory mechanisms
mediated by innate immune cells, but also by stimulating
the chronic activation of CD4+ T cells. Finally, the fact that
CD32 ligation can influence CD4+ T cell activation may
have another important clinical implication. Modulating the
ability of a therapeutic IgG antibody to bind to activating or
inhibitory CD32 could promote the balance in favor of CD4+
T cell activation or suppression. Cellular activation is a desired
characteristic in immunotherapies directed to cancer or in
vaccine generation against infectious diseases. However, when
it comes to chronic inflammation or autoimmune diseases, the
contrary effect is sought, being the suppression of the immune
response a requirement for the induction of immune tolerance.
Thus, therapeutic strategies based on monoclonal IgG antibodies
must take into account the potential modulation on CD4+ T cell
function through their Fc portion as a novel key player.
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